Gilead Sciences, Inc. $GILD Shares Sold by Crew Capital Management Ltd.

Key Points

• Crew Capital Management Ltd. significantly reduced its stake in Gilead Sciences by 63.7% during the 2nd quarter, leaving it with 2,572 shares valued at approximately $285,000.
• Several hedge funds, including Occidental Asset Management LLC and CHICAGO TRUST Co NA, have increased their holdings in Gilead during the same period, indicating mixed institutional sentiment.
• Gilead announced a quarterly dividend of $0.79 per share, with a dividend yield of 2.8%, reflecting the company's financial stability and commitment to returning value to shareholders.

Crew Capital Management Ltd. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 63.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,572 shares of the biopharmaceutical company's stock after selling 4,509 shares during the period. Crew Capital Management Ltd.'s holdings in Gilead Sciences were worth $285,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Occidental Asset Management LLC grew its holdings in Gilead Sciences by 1.4% during the 2nd quarter. Occidental Asset Management LLC now owns 40,670 shares of the biopharmaceutical company's stock worth $4,509,000 after acquiring an additional 551 shares in the last quarter. CHICAGO TRUST Co NA grew its holdings in Gilead Sciences by 25.9% during the 2nd quarter. CHICAGO TRUST Co NA now owns 2,900 shares of the biopharmaceutical company's stock worth $322,000 after acquiring an additional 597 shares in the last quarter. Oliver Luxxe Assets LLC grew its holdings in Gilead Sciences by 5.3% during the 2nd quarter. Oliver Luxxe Assets LLC now owns 62,465 shares of the biopharmaceutical company's stock worth $6,925,000 after acquiring an additional 3,156 shares in the last quarter. Chris Bulman Inc acquired a new position in Gilead Sciences during the 2nd quarter worth $232,000. Finally, Mechanics Bank Trust Department lifted its position in shares of Gilead Sciences by 2.6% in the 2nd quarter. Mechanics Bank Trust Department now owns 10,526 shares of the biopharmaceutical company's stock worth $1,167,000 after buying an additional 266 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

GILD has been the topic of several recent research reports. Rothschild & Co Redburn lifted their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a research report on Friday, September 12th. UBS Group boosted their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a research report on Friday, July 25th. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Finally, Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $117.17.

Gilead Sciences Trading Down 1.4%

Shares of GILD stock opened at $112.49 on Tuesday. Gilead Sciences, Inc. has a 52-week low of $81.83 and a 52-week high of $121.83. The stock has a market cap of $139.58 billion, a price-to-earnings ratio of 22.41, a P/E/G ratio of 0.77 and a beta of 0.36. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a fifty day moving average of $114.11 and a 200-day moving average of $109.95.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. During the same quarter in the prior year, the company posted $2.01 EPS. The business's revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the sale, the chief executive officer owned 595,725 shares of the company's stock, valued at $67,692,231.75. This represents a 1.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This trade represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock worth $9,390,030 in the last quarter. 0.27% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.